References
- R. Paul, W. A. Hallett, ]. W. Hanifin, M.F. Reich, B. D. Johnson, R. H. Lenhard, ].P. Dusza, S. S. Kerwar, Y-i Lin, W. C.Pickett, C. M. Seifert, L. W. Torley, M.E. Tarrant, and S. Wrenn, Preparation ofSubstituted N-Phenyl-4-aryl-2-pyrimidinaminesas Mediator Release Inhibitors, JMed Chem, 36, 2716 (1993) https://doi.org/10.1021/jm00071a002
- P. J. Barnes, New Drugs for Asthma,Nat. Rev. Drug Discov., 3, 831 (2004) https://doi.org/10.1038/nrd1524
- N. Sirisoma, S. Kasibhatla, B. Nguyen, A.Pervin, Y. Wang, G. Claassen, B. Tseng,]. Crewe, and S. X. Cai, Discovery ofSubstituted 4-Anilino-2-(2-pyridyJ)-pyrimidines as a New Series of ApoptosisInducers Using a Cell- and CaspasebasedHigh Throughput Screening Assay.Part 1: Structure-activity Relationships ofthe 4-Anilino Group. Bioorg. Med Chem,14, 7761 (2006) https://doi.org/10.1016/j.bmc.2006.08.002
- S. K. Kelley and A. Ashkenazi, TargetingDeath Receptors in Cancer withApo2L1TRAIL, Curro Opin Pharmacol., 4,333 (2004) https://doi.org/10.1016/j.coph.2004.02.006
- D. R. Batt, G. Bold, S. Kim, T. M.Ramsey, and M. L. Sabio. Preparation ofN-Aryl(heteroarylalkyI)isoquinolineaminesas a Inhibitors of Mutant and Wild-typeMAP Kinases for the Treatment ofCancer. WO 2004080464
- S. Kumar, ]. Boehm, and J. c. Lee, p38MAP Kinases: Key Signalling Moleculesas Therapeutic Targets for InflammatoryDiseases, Nat. Rev. Drug Discov., 2, 717(2003) https://doi.org/10.1038/nrd1177
- J. Dixon, J. Dumas, C. Brennan, H,Hatoum-Mokdad, W. Lee, R. Sibley, andB. Bear, Preparation of 2-Phenylarnino-4-(5-pyrazolylamino)-pyrimidines as KinaseInhibitors, In Particular, SRC KinaseInhibitors. WO 2003026664
- X. Cao., Q.-D. You, Z.i-Y. Li, X.-].Wang, X.-Y. Lu, x.o-R. Liu, D. Xu, andB. Liu, Recent Progress of Src FamilyKinase Inhibitors as Anticancer Agents,Mini Rev. Med Chem 8, 1053 (2008)
- J.-M. Jimenez, G. Bemis, F. Maltais, T.Wang, R. Knegtel, C. Davis, D. Fraysse,D. Boyall, L. Settimo, S. Young, and M.Mortimore, 2-Aminopyridine DerivativesUseful as Kinase Inhibitors, WO2008094992
- M. E. M. Noble, ]. A. Endicott, and L. N.Johnson, The Akt/PKB Family of ProteinKinases: A Review of Small MoleculeInhibitors and Progress towards TargetValidation, Science, 303, 1800 (2004) https://doi.org/10.1126/science.1095920
- P. Kirkpatrick, Kinases: New Route toKinase Inhibition, Nat. Rev. Drug Discov.,5, 104 (2006)
- M. Remuinan, J. J. Gonzalez, C. Del Pozo,A. Francesch, C. Cuevas, S. Munt, and I.Manzanares, Variolin Derivatives andTheir Use as Antitumor Agents, WO2003006457
- B. A. Johns, K. S. Gudmundsson, E. M.Turner, S. H. Allen, V. A. Samano, ]. A.Ray, G. A. Freeman, F. L. Boyd Jr., c. ].Sexton, W. Selleseth, K. L. Creech, andK. R. Moniri, PyrazolopyridineAntiherpetics: SAR of C2' and C7Amine Substituents, Bioorg. Med Chem,13, 2397 (2005) https://doi.org/10.1016/j.bmc.2005.01.044
- M. Hosseini-Sarvari and H. Sharghi, ZnOas a New Catalyst for N-Formylation ofAmines under Solvent-Free Conditions, J.Org. Chern., 71, 6652 (2006) https://doi.org/10.1021/jo060847z
- A. Gopalsamy, H. Yang, ]. W. Ellingboe,]. C. McKew, S. Tam, D.Joseph-McCarthy, W. Zhang, M. Shen,and ]. D. Clark 1,2,4-0xadiazolidin-3,5-diones and 1,3,5-Triazin-2,4,6-triones asCytosolic Phospholipase A2U Inhibitors,Bioorg. Med Chem Lett., 16, 2978(2006) https://doi.org/10.1016/j.bmcl.2006.02.067